Company news
Xiamen Amoytop Biotech Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Announcement on Convening the 2025 Annual Performance and Cash Dividend Briefing
April 2, 2026
Notice on Convening the 2025 Annual General Meeting
April 1, 2026
Announcement on Amending Articles of Association and Some Governance Systems
March 26, 2026
Announcement on the Chairman's Proposal to Repurchase Shares
March 12, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
February 11, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 10, 2026
Announcement on Voluntary Disclosure of a Wholly-owned Subsidiary Passing the High and New Technology Enterprise Certification
February 3, 2026
XIAMEN AMOYTOP BIOTECH CO., LTD. Announcement on Obtaining Notice of Approval for Drug Clinical Trial of ACT100 for Injection
January 30, 2026
Announcement on Voluntary Disclosure of Recognition of the Ninth Batch of National-level Manufacturing Single-Item Champion Enterprises
January 29, 2026
Indicative Announcement on Disclosure of Proposal for Issuing Convertible Corporate Bonds to Non-specific Objects
January 26, 2026
Announcement on Actual Controller Renewing the Concerted Action Agreement
January 16, 2026
Announcement on Completion of Special Account Cancellation for Raised Funds
December 29, 2025
Announcement on Closure of Investment Projects Financed by Raised Funds from Initial Public Offering of Shares
December 19, 2025
Announcement on Resignation of Non-independent Director and Election of Employee Representative Director
December 18, 2025
Announcement on Canceling the Board of Supervisors and Amending the "Articles of Association" and Revising and Formulating Some Corporate Governance Systems
December 2, 2025
Announcement on Changing the Registered Capital and Amending the Articles of Association
November 17, 2025
Announcement on Vesting Results in the 1st Vesting Period of Initial Grant in 2024 Restricted Stock Incentive Plan and Shares Listing
October 27, 2025
Report for Q3 2025
October 22, 2025
Announcement on Approval of the Application for Market Authorization of Additional Indications for Peginterferon alfa-2b Injection
October 12, 2025
Announcement on Resolutions of the 12th Meeting of the 9th Board of Directors
September 26, 2025
Announcement on Granting Partial Reserved Restricted Stocks to Incentive Objects of 2024 Restricted Stock Incentive Plan
September 5, 2025
Announcement on Pegpesen's New Indication Obtaining Drug Clinical Trial Approval Notice
August 21, 2025
Special Report on Semi-annual Deposit and Actual Use of Raised Funds in 2025
August 20, 2025
Announcement on the Completion of Asset Transfer by Wholly-Owned Subsidiary in the Acquisition of Partial Assets of Skyline Therapeutics Limited
July 30, 2025
Announcement on Using Self-owned Funds to Pay Funds Required for Investment Projects Financed by Raised Funds and Replacing Them with an Equal Amount of Raised Funds
July 15, 2025
Announcement on Shareholder with Over 5% Shares Completing Registration for Negotiated Transfer of Some Shares
July 3, 2025
Announcement on the Approval of Yipei Growth Hormone Injection for Marketing
May 29, 2025
Indicative Announcement on Negotiated Transfer of Some Shares and Equity Change by Shareholders Holding More Than 5% Shares
May 22, 2025
Announcement on Attending the 2024 Annual Report Performance Briefing and Online Collective Reception Day for Investors of Listed Companies in Xiamen Jurisdiction
May 7, 2025
Announcement on Implementation of 2024 Annual Dividend Distribution
April 29, 2025
Report for Q1 2025
April 22, 2025
Announcement on Resolution of the 2024 Annual General Meeting
April 18, 2025
Announcement on Attending Annual Collective Performance Briefing for STAR Market Enterprises in Biological Products and CXO Industries in 2024
April 15, 2025
Announcement on Provision of Online Voting Reminder Service for General Meeting
April 10, 2025
2024 Annual Report
March 27, 2025